Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs GlobalFoundries Inc. Ordinary Shares (GFS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs GlobalFoundries Inc. Ordinary Shares — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.14 (market cap $4.02B), while GlobalFoundries Inc. Ordinary Shares trades at $47.99 (market cap $27.28B). The key difference: GlobalFoundries Inc. Ordinary Shares is far larger — about 6.8× Edgewise Therapeutics Inc. Common Stock's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.98% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and GlobalFoundries Inc. Ordinary Shares for 1 Days on average.
| EWTX | GFS | |
|---|---|---|
Market Cap | $4.02B | $27.28B |
Volume | 1,446,128 | 13,755,528 |
Sector | Health | Technology |
52-Week High | $48.35 | $89.96 |
52-Week Low | $14.89 | $32.24 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $3.56B | $26.57B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GlobalFoundries (GFS) trades at $46.70, down 3.39% on the day, with technical indicators showing a neutral to bearish short-term bias. The company maintains solid fundamentals with $6.79B revenue and 10.32% net margin, though profitability declined year-over-year. Recent catalysts include a landmark $21B Japan-backed fab expansion and strategic partnerships with TSMC and Marvell for AI-related semiconductor production, positioning GFS for long-term growth in the semiconductor sector.
While near-term technical weakness persists, GFS's strategic positioning in AI infrastructure and substantial government-backed expansion create compelling long-term opportunities. Risks include execution challenges with massive capital projects and semiconductor cycle volatility. With 57.9% analyst buy ratings and a $79.69 consensus target representing 71% upside, Wall Street remains optimistic about GFS's growth trajectory despite current market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About GlobalFoundries Inc. Ordinary Shares
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →
